---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110344"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:37:13.190937+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Journey Medical Q3 2025 revenue $17.6M (+21% YoY); Emrosi sales $4.9M, prescriptions up 146%

## Summary
- Q3 2025 net revenues $17.6M, up 21% YoY from $14.6M; driven by Emrosi launch.
- Emrosi net sales $4.9M; prescriptions increased 146% sequentially vs Q2 2025.
- Net loss narrowed to $2.3M ($0.09/sh) from $2.4M ($0.12/sh) in Q3 2024.
- Adjusted EBITDA improved to positive $1.7M vs $0.3M in prior-year quarter.
- Gross margin 67.4% vs 69.4% in Q3 2024 (prior year benefited from one-time adjustments).

## SEC filing metadata
- accession: 0001104659-25-110344
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465925110344/0001104659-25-110344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465925110344/tm2530914d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110344
- JSON: https://secwatch.observer/filing/0001104659-25-110344.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.